Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/WTAP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/WTAP_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/WTAP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/WTAP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/WTAP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/WTAP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/WTAP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/WTAP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/WTAP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000838024 | Breast | DCIS | RNA splicing | 73/1390 | 434/18723 | 3.05e-11 | 5.08e-09 | 73 |
GO:004348424 | Breast | DCIS | regulation of RNA splicing | 36/1390 | 148/18723 | 1.40e-10 | 1.69e-08 | 36 |
GO:000037524 | Breast | DCIS | RNA splicing, via transesterification reactions | 58/1390 | 324/18723 | 2.89e-10 | 3.34e-08 | 58 |
GO:000037724 | Breast | DCIS | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:000039824 | Breast | DCIS | mRNA splicing, via spliceosome | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:004802424 | Breast | DCIS | regulation of mRNA splicing, via spliceosome | 23/1390 | 101/18723 | 1.02e-06 | 4.04e-05 | 23 |
GO:005068423 | Breast | DCIS | regulation of mRNA processing | 24/1390 | 137/18723 | 6.71e-05 | 1.33e-03 | 24 |
GO:190331123 | Breast | DCIS | regulation of mRNA metabolic process | 40/1390 | 288/18723 | 9.26e-05 | 1.71e-03 | 40 |
GO:000038123 | Breast | DCIS | regulation of alternative mRNA splicing, via spliceosome | 13/1390 | 60/18723 | 3.78e-04 | 5.27e-03 | 13 |
GO:000038023 | Breast | DCIS | alternative mRNA splicing, via spliceosome | 15/1390 | 77/18723 | 4.70e-04 | 6.20e-03 | 15 |
GO:000838016 | Endometrium | AEH | RNA splicing | 111/2100 | 434/18723 | 2.42e-17 | 1.12e-14 | 111 |
GO:004348416 | Endometrium | AEH | regulation of RNA splicing | 55/2100 | 148/18723 | 1.28e-16 | 5.49e-14 | 55 |
GO:000037515 | Endometrium | AEH | RNA splicing, via transesterification reactions | 88/2100 | 324/18723 | 1.11e-15 | 3.91e-13 | 88 |
GO:000037715 | Endometrium | AEH | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 87/2100 | 320/18723 | 1.51e-15 | 4.78e-13 | 87 |
GO:000039815 | Endometrium | AEH | mRNA splicing, via spliceosome | 87/2100 | 320/18723 | 1.51e-15 | 4.78e-13 | 87 |
GO:004802416 | Endometrium | AEH | regulation of mRNA splicing, via spliceosome | 40/2100 | 101/18723 | 1.56e-13 | 4.27e-11 | 40 |
GO:190331110 | Endometrium | AEH | regulation of mRNA metabolic process | 77/2100 | 288/18723 | 1.69e-13 | 4.40e-11 | 77 |
GO:005068410 | Endometrium | AEH | regulation of mRNA processing | 42/2100 | 137/18723 | 6.05e-10 | 5.67e-08 | 42 |
GO:00003809 | Endometrium | AEH | alternative mRNA splicing, via spliceosome | 26/2100 | 77/18723 | 1.28e-07 | 5.97e-06 | 26 |
GO:00003819 | Endometrium | AEH | regulation of alternative mRNA splicing, via spliceosome | 20/2100 | 60/18723 | 4.46e-06 | 1.17e-04 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WTAP | SNV | Missense_Mutation | | c.152N>C | p.Asp51Ala | p.D51A | Q15007 | protein_coding | tolerated(0.07) | possibly_damaging(0.78) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
WTAP | SNV | Missense_Mutation | | c.236G>A | p.Arg79Gln | p.R79Q | Q15007 | protein_coding | deleterious(0.04) | benign(0.38) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
WTAP | SNV | Missense_Mutation | rs375840138 | c.1001N>T | p.Ala334Val | p.A334V | Q15007 | protein_coding | tolerated_low_confidence(0.33) | benign(0) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
WTAP | SNV | Missense_Mutation | | c.485N>C | p.Arg162Pro | p.R162P | Q15007 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-D8-A1XB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WTAP | SNV | Missense_Mutation | rs369657864 | c.932A>G | p.Asn311Ser | p.N311S | Q15007 | protein_coding | tolerated_low_confidence(0.51) | benign(0.025) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WTAP | insertion | Nonsense_Mutation | novel | c.573_574insCCAACTGCACTCCAGCCTGGGCTACAGAGTGAGACTCCATCCTAA | p.Lys191_Lys192insProThrAlaLeuGlnProGlyLeuGlnSerGluThrProSerTer | p.K191_K192insPTALQPGLQSETPS* | Q15007 | protein_coding | | | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
WTAP | insertion | Frame_Shift_Ins | novel | c.929_930insCTTGCTTTGTGGCAGGCAC | p.Asn311LeufsTer7 | p.N311Lfs*7 | Q15007 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WTAP | insertion | Frame_Shift_Ins | novel | c.931_932insAAGAAACATTTTTCAATGTT | p.Asn311LysfsTer26 | p.N311Kfs*26 | Q15007 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WTAP | SNV | Missense_Mutation | novel | c.1082A>G | p.Asp361Gly | p.D361G | Q15007 | protein_coding | deleterious_low_confidence(0.01) | benign(0.084) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
WTAP | SNV | Missense_Mutation | | c.448N>C | p.Asp150His | p.D150H | Q15007 | protein_coding | deleterious(0.03) | probably_damaging(0.98) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |